Study sheds light on deadly childhood cancer

LONDON (Reuters) - A gene involved in cell division also helps fuel a deadly childhood cancer called neuroblastoma and could offer a new way to develop drugs to treat the disease, German researchers said on Monday.

The study published in the journal Cancer Cell found that a protein produced by the AURKA gene feeds a different gene called MYCN, which scientists know plays a key role in fuelling tumor growth in children with neuroblastoma, the researchers said.

“The MYCN gene is one that no pharmaceutical company have been able to target,” Martin Eilers, a researcher at Wurzburg University in Germany, who led the study, said in a telephone interview.

“Our finding offers hope we can make new (drugs) to attack this cancer.”

Neuroblastoma accounts for 15 percent of childhood cancer deaths, with just a 40 percent survival rate, even though it only causes about seven percent of all pediatric cancers.

In August U.S. researchers said they had found a variation in a gene called ALK that causes most inherited forms of the disease by helping cells proliferate. Out-of-control proliferation is the hallmark of cancer.

Eilers and his team screened 200 genes dependent on MYCN in children with neuroblastoma and found that the protein produced by AURKA was key to the wild cell growth.

Current drugs that inhibit cell growth will not work but AURKA is a promising target for new treatments because there are already substances in the body that attack the protein. That means, in theory, newly developed drugs could do the same.

“This is potentially a way you can get at and interrupt these tumors,” Eilers said in a telephone interview.

(Reporting by Michael Kahn; editing by Maggie Fox and Jon Boyle)


Related Posts:

By Megan Rauscher NEW YORK (Reuters Health) - Blocking certain proteins in cells may be a way to attack ovarian cancer, researchers said at the annual meeting of the American Society for Cell Biology underway in San Francisco. For growth and proliferation, ovarian cancer cells are “addicted” to a family of proteins produced by the cancer-promoting gene

Full Post: Possible way to treat ovarian cancer reported

LONDON (Reuters) - The most commonly used breast cancer drug may cause tumors to spread in a small number of women with low levels of a protein which makes cells stick together, British researchers said on Thursday. The findings could lead to new tests to determine which women are not likely to benefit from tamoxifen and

Full Post: Study sheds light on breast cancer drug failure

By Julie Steenhuysen CHICAGO (Reuters) - A single gene appears to play a crucial role in deadly breast cancers, increasing the chances the cancer will spread and making it resistant to chemotherapy, U.S. researchers said on Monday. They found people with aggressive breast cancers have abnormal genetic alterations in a gene called MTDH, and drugs that block

Full Post: Scientists find a gene that makes cancer spread

By Michael Kahn LONDON (Reuters) - British scientists have figured out why some women develop resistance to the most commonly used breast cancer drug, something that raises the risk their tumors will return, according to a study published on Wednesday. The findings could lead to new tests to determine which women are not likely to benefit from

Full Post: Scientists unravel breast cancer drug resistance

CHICAGO (Reuters) - U.S. researchers have found a way to switch on a cell-killing protein in the body, a finding that could lead to new ways to treat diseases like cancer in which cells grow out of control. The body naturally activates this protein, called BAX, to kill off unwanted or defective cells in a process

Full Post: Researchers find trigger for killer protein

Site Navigation

Most Read